A Randomized, Double-Blind, Single-dose and Multi-dose Study of the Novel Retinoid, 9cUAB30 to Determine Pharmacokinetics and Safety.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs 9cUAB30 (Primary)
- Indications Cancer
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 09 Oct 2014 Biomarkers information updated
- 08 Aug 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 28 Nov 2011 Actual initiation date (Oct 2011) added as reported by ClinicalTrials.gov.